|
1
|
Rastogi B, Kumar A, Raut SK, Panda NK,
Rattan V, Joshi N and Khullar M: Downregulation of miR-377 promotes
oral squamous cell carcinoma growth and migration by targeting
HDAC9. Cancer Investigation. 35:152–162. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Warnakulasuriya S: Causes of oral
cancer-an appraisal of controversies. Br Dent J. 207:471–475.
2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gharat SA, Momin M and Bhavsar C: Oral
squamous cell carcinoma: Current treatment strategies and
nanotechnology-based approaches for prevention and therapy. Crit
Rev Ther Drug Carrier Syst. 33:363–400. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pollaers K, Hinton-Bayre A, Friedland PL
and Farah CS: AJCC 8th edition oral cavity squamous cell carcinoma
Staging-is it an improvement on the AJCC 7th edition? Oral Oncol.
82:23–28. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lambert R, Sauvaget C, de Camargo Cancela
M and Sankaranarayanan R: Epidemiology of cancer from the oral
cavity and oropharynx. Eur J Gastroenterol Hepatol. 23:633–641.
2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yokoyama T and Nakamura T: Tribbles in
disease: Signaling pathways important for cellular function and
neoplastic transformation. Cancer Sci. 102:1115–1122.
2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li K, Wang F, Cao WB, Lv XX, Hua F, Cui B,
Yu JJ, Zhang XW, Shang S, Liu SS, et al: TRIB3 promotes APL
progression through stabilization of the oncoprotein PML-RARα and
inhibition of p53-mediated senescence. Cancer Cell. 31:697–710.e7.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Miyoshi N, Ishii H, Mimori K, Takatsuno Y,
Kim H, Hirose H, Sekimoto M, Doki Y and Mori M: Abnormal expression
of TRIB3 in colorectal cancer: A novel marker for prognosis. Br J
Cancer. 101:1664–1670. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Izrailit J, Jaiswal A, Zheng W, Moran MF
and Reedijk M: Cellular stress induces TRB3/USP9x-dependent Notch
activation in cancer. Oncogene. 36:1048–1057. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hua F, Mu R, Liu J, Xue J, Wang Z, Lin H,
Yang H, Chen X and Hu Z: TRB3 interacts with SMAD3 promoting tumor
cell migration and invasion. J Cell Sci. 124:3235–3246.
2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wennemers M, Bussink J, Scheijen B,
Nagtegaal ID, van Laarhoven HW, Raleigh JA, Varia MA, Heuvel JJ,
Rouschop KM, Sweep FC and Span PN: Tribbles homolog 3 denotes a
poor prognosis in breast cancer and is involved in hypoxia
response. Breast Cancer Res. 13(R82)2011.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Zhou H, Luo Y, Chen JH, Hu J, Luo YZ, Wang
W, Zeng Y and Xiao L: Knockdown of TRB3 induces apoptosis in human
lung adenocarcinoma cells through regulation of Notch 1 expression.
Mol Med Rep. 8:47–52. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hua F, Shang S, Yang YW, Zhang HZ, Xu TL,
Yu JJ, Zhou DD, Cui B, Li K, Lv XX, et al: TRIB3 interacts With
β-catenin and TCF4 to increase stem cell features of colorectal
cancer stem cells and tumorigenesis. Gastroenterology.
156:708–721.e15. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hong B, Zhou J, Ma K, Zhang J, Xie H,
Zhang K, Li L, Cai L, Zhang N, Zhang Z and Gong K: TRIB3 promotes
the proliferation and invasion of renal cell carcinoma cells via
activating mapk signaling pathway. Int J Biol Sci. 15:587–597.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Song M, Bode AM, Dong Z and Lee MH: AKT as
a therapeutic target for cancer. Cancer Res. 79:1019–1031.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
http://tcga.xenahubs.net/download/TCGA.HNSC.sampleMap/HiSeqV2.gz.
|
|
18
|
Wang Y, Liu DP, Chen PP, Koeffler HP, Tong
XJ and Xie D: Involvement of IFN regulatory factor (IRF)-1 and
IRF-2 in the formation and progression of human esophageal cancers.
Cancer Res. 67:2535–2543. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vatandoost J and Kafi Sani K: A Study of
recombinant Factor IX in drosophila insect S2 cell lines through
transient gene expression technology. Avicenna J Med Biotechnol.
10:265–268. 2018.PubMed/NCBI
|
|
20
|
Simpson DR, Mell LK and Cohen EE:
Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of
the head and neck. Oral Oncol. 51:291–298. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang J, Wen HJ, Guo ZM, Zeng MS, Li MZ,
Jiang YE, He XG and Sun CZ: TRB3 overexpression due to endoplasmic
reticulum stress inhibits AKT kinase activation of tongue squamous
cell carcinoma. Oral Oncol. 47:934–939. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wennemers M, Bussink J, Grebenchtchikov N,
Sweep FC and Span PN: TRIB3 protein denotes a good prognosis in
breast cancer patients and is associated with hypoxia sensitivity.
Radiother Oncol. 101:198–202. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Revathidevi S and Munirajan AK: Akt in
cancer: Mediator and more. Semin Cancer Biol. 59:80–91.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ikink GJ, Boer M, Bakker ER and Hilkens J:
IRS4 induces mammary tumorigenesis and confers resistance to
HER2-targeted therapy through constitutive PI3K/AKT-pathway
hyperactivation. Nat Commun. 7(13567)2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ediriweera MK, Tennekoon KH and Samarakoon
SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer:
Biological and Therapeutic Significance. Semin Cancer Biol.
59:147–160. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Restelli M, Magni M, Ruscica V, Pinciroli
P, De Cecco L, Buscemi G, Delia D and Zannini L: A novel crosstalk
between CCAR2 and AKT pathway in the regulation of cancer cell
proliferation. Cell Death Dis. 7(e2453)2016.PubMed/NCBI View Article : Google Scholar
|
